Key result
In patients at high/very-high CV risk without heart failure, ACE inhibitors reduced CV mortality compared to placebo and provided greater reduction than ARBs.
Why the study?
To assess the impact of ACE-Is and ARBs on all-cause and CV mortality, as well as CV, cerebrovascular, and renal outcomes in patients at high/very-high CV risk without heart failure.
Do ACE-Is and ARBs reduce mortality and cardiovascular events in patients at high/very-high CV risk without heart failure?
Meta-Analysis (n=87,908)
double-blind
randomized
Do ACE-Is and ARBs reduce mortality and cardiovascular events in patients at high/very-high CV risk without heart failure?
In patients at high/very-high CV risk without heart failure, ACE inhibitors demonstrated a significant reduction in all-cause and CV mortality compared to placebo, whereas ARBs did not, suggesting ACE inhibitors should be preferred for CV protection.
Answers are grounded in this paper and cite their sources.
Supports preferring ACE inhibitors over ARBs for CV protection in high-risk patients without HF; confirms mortality benefit vs placebo not seen with ARBs.
Aims To assess the impact of angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs) on all-cause and cardiovascular (CV) mortality, as well as CV, cerebrovascular, and renal outcomes in patients at high/very-high CV risk without heart failure by a systematic review and meta-analysis of placebo-controlled, double-blind, randomized trials. Methods and results The CENTRAL, ClinicalTrials.gov, Ovid-MEDLINE, Ovid-Embase, Science Citation Index-Expanded, and WHO-ICTRP databases were searched between August and September 2023. Heart failure trials were excluded. The hypothesis of a homogeneous treatment effect between ACE-Is and ARBs was tested with a Cochran’s Q statistic. The protocol for the systematic review was registered on PROSPERO (CRD42023452406) and the study reported as per PRISMA guidelines. 17 trials (9 ACE-Is and 8 ARBs, total of 87 908 participants) were included. The event rates for all-cause mortality, CV mortality, and major CV events (MACEs) did not differ in the parallel placebo arms of ACE-I and ARB trials; however, compared to placebo, ACE-Is reduced the rate of CV mortality [hazard ratio (HR) 0.88; 95% confidence interval (CI) 0.78–0.99], all-cause mortality (HR 0.92; 95% CI 0.85–0.99) and myocardial infarction (HR 0.83; 95% CI 0.73–0.94), while ARBs did not. The rates of HF, stroke, and MACEs were significantly reduced by both drug classes. Angiotensin-converting enzyme inhibitors induced a greater reduction of CV mortality than ARBs (Q = 4.59; P-value = 0.03). Conclusion In patients at high/very-high CV risk, ACE-Is were more protective against CV mortality than ARBs, supporting their preferential use for CV protection.
No takes yet. Share an insight, caveat, or question.
Masi et al. (2026) conducted a meta-analysis in high/very-high cardiovascular risk without heart failure (n=87,908). Angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs) vs. Placebo was evaluated on Cardiovascular mortality (HR 0.88, 95% CI 0.78-0.99). In patients at high/very-high CV risk without heart failure, ACE inhibitors reduced CV mortality compared to placebo and provided greater reduction than ARBs.
Synapse has enriched 10 related papers. Consider them for comparative context: